Camp4 Therapeutics Corp
CAMP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CAMP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CAMP
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies to upregulate protein expression, with its lead candidate in early clinical trials and strategic partnerships with GlaxoSmithKline and BioMarin.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies to upregulate protein expression, with its lead candidate in early clinical trials and strategic partnerships with GlaxoSmithKline and BioMarin.
- Camp4 Therapeutics was founded in 2015 and focuses on its RAP Platform for gene upregulation, primarily in CNS and other tissues [sec_mda · as of 2026-05-07].
- The company has strategic discovery partnerships with GlaxoSmithKline and a research collaboration with BioMarin Pharmaceutical Inc. [sec_mda · as of 2026-05-07][sec_mda · as of 2025-05-13].
- As of June 30, 2026, Camp4 reported cash and equivalents of $88.0M, total revenue of $1.8M, and a net loss of $33.5M [sec].
- The company has no approved products and has not generated any revenue from product sales; it expects to need substantial additional funding [sec_mda · as of 2026-03-05].
- Based on its cash position as of September 30, 2025 ($75.3M), management estimated sufficient runway into 2027, but this is subject to assumptions [sec_mda · as of 2025-11-06].
What works
- Camp4 has established strategic partnerships with GlaxoSmithKline and BioMarin, which may provide validation and non-dilutive funding for its RAP Platform [sec_mda · as of 2026-05-07][sec_mda · as of 2025-05-13].
- The company's RAP Platform targets regRNA sequences to upregulate protein expression, a novel approach that could address diseases with haploinsufficiency [sec_mda · as of 2026-05-07].
- As of September 30, 2025, Camp4 had cash and cash equivalents of $75.3 million, with an estimated runway into 2027 based on current operating plans [sec_mda · as of 2025-11-06].
What to weigh
- Camp4 has no approved products and has never generated revenue from product sales; profitability is uncertain and may never be achieved [sec_mda · as of 2026-03-05].
- The company has incurred significant operating losses and expects to continue incurring losses for the foreseeable future as it advances its pipeline [sec_mda · as of 2025-11-06].
- Camp4's future viability depends on its ability to raise additional capital, and there is no assurance that sufficient funding will be obtained on acceptable terms [sec_mda · as of 2025-05-13].
- The company faces substantial doubt about its ability to continue as a going concern, as noted in its SEC filings [sec_mda · as of 2025-05-13].
From the filings
Quoted directly from source documents.
Camp4 has no approved products and no product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · March 5, 2026
Camp4 has a strategic partnership with GlaxoSmithKline.
“strategic discovery partnerships, including our research, collaboration, and license agreement with GlaxoSmithKline”
SEC MD&A · May 7, 2026
Camp4's cash position as of September 30, 2025 was $75.3 million.
“As of September 30, 2025, we had cash and cash equivalents of $75.3 million.”
SEC MD&A · November 6, 2025
Camp4's future viability is dependent on raising additional capital.
“Our future viability is dependent on our ability to generate cash from our operating activities or to raise additional capital to finance our operations.”
SEC MD&A · May 13, 2025
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Camp4 has no approved products and has never generated product revenue; profitability is uncertain [sec_mda · as of 2026-03-05].
- Need for substantial additional funding — The company expects to need substantial additional funding to support operations and may not secure it on acceptable terms [sec_mda · as of 2026-03-05].
- Going concern uncertainty — As of May 2025, there was substantial doubt about Camp4's ability to continue as a going concern [sec_mda · as of 2025-05-13].
- Clinical and regulatory risks — Product candidates may fail in clinical trials or not receive regulatory approval, which would delay or prevent commercialization [sec_mda · as of 2026-03-05].
What to watch
- Progress of clinical trials for lead product candidates and any updates on safety or efficacy data [sec_mda · as of 2026-05-07].
- Ability to secure additional financing or partnership milestones to extend cash runway beyond 2027 [sec_mda · as of 2025-11-06].
- Updates from strategic collaborations with GlaxoSmithKline and BioMarin, including potential milestone payments [sec_mda · as of 2026-05-07][sec_mda · as of 2025-05-13].
- Regulatory feedback from the FDA or other authorities that could impact clinical development plans [sec_mda · as of 2026-03-05].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Camp4 Therapeutics Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Camp4 Therapeutics Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
21.0 months
OCF -$13M · Net income -$34M
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
5 buys · 4 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$147.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 12,615,272 | $55.8M |
| fmr llc | 4,933,432 | $21.8M |
| vanguard capital management llc | 3,069,536 | $13.5M |
| balyasny asset management l.p. | 2,632,437 | $11.6M |
| enavate sciences gp, llc | 2,190,920 | $9.7M |
| adage capital partners gp, l.l.c. | 1,960,784 | $8.6M |
| stonepine capital management, llc | 1,389,622 | $6.1M |
| harbourvest partners llc | 1,271,948 | $5.6M |
| silverarc capital management, llc | 653,594 | $2.9M |
| blackrock, inc. | 456,371 | $2.0M |
Showing top 10 of 43 institutional holders of Camp4 Therapeutics Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.3%
- Days to cover
- 6.0
- Shares short
- 450,462
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CAMP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Camp4 Therapeutics Corp?
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies to upregulate protein expression, with its lead candidate in early clinical trials and strategic partnerships with GlaxoSmithKline and BioMarin.
What is Camp4 Therapeutics Corp's lead drug candidate?
Camp4 Therapeutics Corp's most advanced tracked candidate is cmp-001 (Phase 1) for Urea cycle disorders (UCDs).
Who is the CEO of Camp4 Therapeutics Corp?
Mr. Joshua Mandel-Brehm is the chief executive officer of Camp4 Therapeutics Corp (CAMP).
Where is Camp4 Therapeutics Corp headquartered?
Camp4 Therapeutics Corp (CAMP) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Camp4 Therapeutics Corp focus on?
Camp4 Therapeutics Corp develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.